Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Anlotinib in combination with pembrolizumab for low-grade myofibroblastic sarcoma of the pancreas: A case report
Rong-Ting Wu, Ji-Cheng Zhang, Cheng-Nan Fang, Xiao-Yu Qi, Jin-Fei Qiao, Ping Li, Li Su
Rong-Ting Wu, Xiao-Yu Qi, Jin-Fei Qiao, Graduate School of Anhui University of Chinese Medicine, Anhui University of Chinese Medicine, Hefei 230022, Anhui Province, China
Rong-Ting Wu, Xiao-Yu Qi, Jin-Fei Qiao, Ping Li, Li Su, Department of Chinese Integrative Medicine Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China
Ji-Cheng Zhang, Oncology and General Practice, Suzhou Hospital of Traditional Chinese Medicine, Suzhou 234000, Anhui Province, China
Cheng-Nan Fang, The First Clinical College of Anhui Medical University, Anhui Medical University, Hefei 230022, Anhui Province, China
Author contributions: Wu RT, Zhang JC, Fang CN, QI XY, Qiao JF, LI P, and Su L designed the research scheme; Wu RT, Zhang JZ, Fang CN, and Li P carried out the research; Qi XY and Qiao JF conducted data collection and related chart making; Wu RT, Zhang CC, and Su L wrote the manuscript; All authors read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Li Su, Doctor, Deputy Director, Department of Chinese Integrative Medicine Oncology, The First Affiliated Hospital of Anhui Medical University, No. 120 Wanshui Road, Shushan District, Hefei 230022, Anhui Province, China. 13615606829@163.com
Received: September 5, 2023
Peer-review started: September 5, 2023
First decision: November 13, 2023
Revised: November 25, 2023
Accepted: December 1, 2023
Article in press: December 1, 2023
Published online: December 16, 2023
BACKGROUND
Low-grade myofibroblastic sarcoma (LGMS) is a rare spindle cell sarcoma especially in the pancreas, with myofibroblastic differentiation. Hitherto, only a few cases have been reported.
CASE SUMMARY
Herein, we report a case involving the discovery of a pancreatic mass detected during a routine physical examination. Subsequent imaging and pathological tests of the patient led to the diagnosis of LGMS of the pancreas. Following surgical intervention, the patient experienced recurrence and metastasis. Conventional treatment is not effective for postoperative recurrent pancreatic LGMS with multiple metastases. After communicating with the patients and their families, informed consent was obtained for the treatment of anlotinib combined with pembrolizumab. Evaluation of imaging and clinical symptoms post-treatment revealed a relatively favorable response to the combination of anlotinib and pembrolizumab.
CONCLUSION
Based on the comprehensive literature review, our report aimed to provide evidence for a better understanding of the disease characteristics, diagnostic criteria, imaging findings, and identification of LGMS. And explore novel treatment strategies for this disease.
Core Tip: Low-grade myofibroblastic sarcoma (LGMS) is a rare spindle cell sarcoma with myofibroblastic differentiation. It is predominantly located in the head, neck, and extremities, whereas less frequently in the abdominal cavity, especially the pancreatic region. LGMS is characterized by a low-grade malignancy and low risk of recurrence and metastases. To date, complete surgical resection remains the primary treatment modality. Despite chemoradiotherapy showing anti-tumor activity for the treatment of postoperative recurrence and metastasis, it remains controversial. Until recently, no effective treatment for LGMS patients intolerant to chemoradiotherapy has been well established. This article aims to explore the new idea of LGMS based on literature obtained from PubMed and a clinical case.
